Intrathecal Dexmedetomidine and Postoperative Delirium in Elderly Hip Fracture Surgery

NCT07810556 | Not Yet Recruiting Phase 2

• 1 other identifier: IT Dexmedetomidine & Delirium
• Study Type: interventional
• Target: 130
• Locations: 0 countries
• Sites: N/A

Brief Summary

Postoperative delirium (POD) is a common and serious complication in elderly patients undergoing surgical repair for hip fractures, often triggered by acute pain, surgical stress, neuroinflammation, and opioid consumption. Although spinal anesthesia using bupivacaine is commonly performed, local anesthetics alone often require additional systemic rescue opioids for postoperative pain relief, which can further increase delirium risk. Dexmedetomidine is a selective alpha-2 adrenergic agonist that has demonstrated neuroprotective, anti-inflammatory, and opioid-sparing effects. The purpose of this clinical trial is to evaluate whether adding intrathecal dexmedetomidine as an adjuvant to hyperbaric bupivacaine during spinal anesthesia reduces the incidence and severity of postoperative delirium compared to hyperbaric bupivacaine alone in geriatric patients undergoing hip fracture surgeries. Participants will be randomly assigned to one of two groups:

• Dexmedetomidine Group: Receives hyperbaric bupivacaine 0.5% (10 mg) combined with 5 µg dexmedetomidine intrathecally.
• Control Group: Receives hyperbaric bupivacaine 0.5% (10 mg) combined with normal saline intrathecally. The primary outcome is the incidence of postoperative delirium evaluated using the Confusion Assessment Method (CAM) twice daily during the first 48 hours following surgery. Secondary assessments include the duration and severity of delirium episodes, spinal block characteristics, hemodynamic stability, postoperative pain scores, rescue analgesic consumption, sedation levels, adverse events, and total hospital length of stay.

Conditions

Postoperative Delirium; Hip Fractures

Keywords

Dexmedetomidine; Bupivacaine; Spinal Anesthesia; Intrathecal Adjuvant; Geriatric Anesthesia; Confusion Assessment Method

Outcome Measures

Primary Outcomes (1)

• Incidence of Postoperative Delirium Assessed by the Confusion Assessment Method (CAM)

  Incidence is defined as the presence of postoperative delirium, assessed using the Confusion Assessment Method (CAM). A participant is considered positive for delirium if they exhibit Feature 1 (acute onset and fluctuating course) and Feature 2 (inattention), plus either Feature 3 (disorganized thinking) or Feature 4 (altered level of consciousness). Assessments are conducted twice daily.

  48 hours

Study Arms (2)

Group D: Dexmedetomidine Group

EXPERIMENTAL

Patients will receive an intrathecal injection consisting of hyperbaric bupivacaine 0.5% (10 mg, 2.0 mL) plus 5 µg dexmedetomidine (diluted in normal saline to 0.5 mL), yielding a total volume of 2.5 mL administered via lumbar puncture at the L3-L4 or L4-L5 interspace.

Drug: Dexmedetomidine

Group C: Control Group

ACTIVE COMPARATOR

Patients will receive an intrathecal injection consisting of hyperbaric bupivacaine 0.5% (10 mg, 2.0 mL) plus 0.5 mL normal saline, yielding an identical total volume of 2.5 mL administered via lumbar puncture at the L3-L4 or L4-L5 interspace.

Drug: Hyperbaric Bupivacaine with Normal Saline

Interventions

Dexmedetomidine DRUG

A single intrathecal dose of 5 µg dexmedetomidine (diluted in normal saline to 0.5 mL) combined with hyperbaric bupivacaine 0.5% (10 mg, 2.0 mL), administered via lumbar puncture prior to surgery.

Group D: Dexmedetomidine Group

Hyperbaric Bupivacaine with Normal Saline DRUG

A single intrathecal injection of hyperbaric bupivacaine 0.5% (10 mg, 2.0 mL) combined with 0.5 mL of 0.9% normal saline (placebo volume equivalent), administered via lumbar puncture prior to surgery.

Group C: Control Group

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• Elderly patients aged 65 years or older.
• American Society of Anesthesiologists (ASA) physical status I, II, or III.
• Patients scheduled for elective or emergency hip fracture surgeries (e.g., internal fixation, hemiarthroplasty, or total hip arthroplasty).
• Eligible for and scheduled to undergo the procedure under spinal anesthesia.
• Written informed consent provided by the patient or their legally authorized representative.

You may not qualify if:

• Patient or legal representative refusal to participate in the study or receive spinal anesthesia.
• Absolute contraindications to spinal anesthesia (e.g., coagulopathy, bleeding disorders, localized infection at the puncture site, or severe hypovolemia).
• Pre-existing cognitive or neurological impairment (diagnosed dementia, baseline Mini-Mental State Examination \[MMSE\] score \< 24, history of recent stroke, severe psychiatric illness, or chronic use of sedatives/antidepressants).
• Cardiovascular contraindications (baseline bradycardia with heart rate \< 50 beats/min, advanced second- or third-degree atrioventricular block, or severe baseline hypotension with mean arterial pressure \< 65 mmHg).
• Severe end-stage organ failure (severe hepatic or renal impairment).
• Severe auditory or visual impairment hindering proper cognitive evaluation, or inability to communicate.
• Intraoperative failure of spinal anesthesia requiring conversion to general anesthesia, surgical duration exceeding 2 hours, or massive intraoperative blood loss/hemodynamic instability.

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Emergence Delirium; Hip Fractures

Interventions

Dexmedetomidine; Saline Solution

Condition Hierarchy (Ancestors)

Delirium; Confusion; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Postoperative Complications; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Neurocognitive Disorders; Mental Disorders; Femoral Fractures; Fractures, Bone; Wounds and Injuries; Hip Injuries; Leg Injuries

Intervention Hierarchy (Ancestors)

Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Crystalloid Solutions; Isotonic Solutions; Solutions; Pharmaceutical Preparations

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident

Study Record Dates

• First Submitted: September 3, 2026
• First Posted: September 9, 2026
• Study Start: October 1, 2026
• Primary Completion (Estimated): October 1, 2027
• Study Completion (Estimated): November 1, 2027
• Last Updated: September 9, 2026

Record last verified: 2026-09